M. Ye

发表

Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

D. Batlle, A. Fogo, Mark J. Osborn, 2017, Kidney international.

Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2: Prevention of Angiotensin II–Dependent Hypertension

J. Penninger, D. Batlle, M. Schuster, 2010, Hypertension.

Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy

D. Batlle, Jessica Navarro, M. Molitch, 2022, Kidney international reports.

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

D. Batlle, Ivan Cokic, M. Soler, 2006, Journal of the American Society of Nephrology : JASN.

A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection

G. Randall, J. Henkin, D. Missiakas, 2022, Journal of the American Society of Nephrology : JASN.

A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids.

A. Gupta, G. Randall, D. Batlle, 2021, Journal of the American Society of Nephrology : JASN.

Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19

D. Batlle, M. Soler, J. Wysocki, 2020, bioRxiv.

Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

D. Batlle, J. Wysocki, M. Bader, 2019, Hypertension.

Murine Recombinant Angiotensin-Converting Enzyme 2: Effect on Angiotensin II–Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2

D. Batlle, M. Schuster, J. Wysocki, 2012, Hypertension.

ACE and ACE2 Activity in Diabetic Mice

D. Batlle, T. Coffman, K. Bernstein, 2006, Diabetes.

Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation.

D. Batlle, L. Wilsbacher, S. Quaggin, 2018, Kidney international.

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.

D. Batlle, M. Soler, J. Wysocki, 2009, American journal of physiology. Renal physiology.

Transcription Factor 21 Is Required for Branching Morphogenesis and Regulates the Gdnf-Axis in Kidney Development.

Y. Akimoto, K. Yokote, Chengjin Li, 2018, Journal of the American Society of Nephrology : JASN.

Knockout of aminopeptidase A in mice causes functional alterations and morphological glomerular basement membrane changes in the kidneys.

D. Batlle, Y. Kanwar, J. Wysocki, 2020, Kidney international.

Urinary Renin in Patients and Mice With Diabetic Kidney Disease.

D. Batlle, M. Afkarian, P. Vallés, 2019, Hypertension.

Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus

A. Rademaker, R. Nelson, D. Batlle, 2019, Physiological reports.

A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13

D. Batlle, J. Wysocki, P. Serfozo, 2017, Scientific Reports.

Enhanced reactive-oxygen-species generation and photocatalytic efficiency with internal imide structures of different ratio in metal-free perylene-g-C3N4 semiconductors

Long Jiang, Fei Liu, Yong Zhou, 2021 .

Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II

A. Schmaier, C. Flask, B. Hoit, 2017, Journal of Molecular Medicine.

Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.

D. Batlle, J. Wysocki, M. Ye, 2015, American journal of hypertension.

ACE2 deficiency increases NADPH‐mediated oxidative stress in the kidney

D. Batlle, J. Wysocki, M. Sparks, 2014, Physiological reports.

Regulation of urinary ACE2 in diabetic mice.

D. Batlle, K. Burns, J. Wysocki, 2013, American journal of physiology. Renal physiology.

Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic Mice: A Renoprotective Combination?

D. Batlle, J. Wysocki, Minghao Ye, 2004, Hypertension.

Isolation and genomic characterization of a pathogenic Providencia rettgeri strain G0519 in turtle Trachemys scripta

Minghao Ye, Jingfeng Sun, Chengxun Chen, 2020, Antonie van Leeuwenhoek.

Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice.

A. Fawzi, D. Batlle, Jonathan C. Chou, 2014, Investigative ophthalmology & visual science.

Apelinergic system in the kidney: implications for diabetic kidney disease

D. Batlle, J. Wysocki, M. Bader, 2018, Physiological reports.

ACE2 and Diabetes: ACE of ACEs?

D. Batlle, Minghao Ye, María José Soler, 2010, Diabetes.

Regulation of urinary ACE 2 in diabetic mice

D. Batlle, K. Burns, J. Wysocki, 2013 .

Evaluation of Renal Hypoxia in Diabetic Mice by BOLD MRI

Pottumarthi Prasad, D. Batlle, P. Prasad, 2010, Investigative radiology.

Angiotensin-Converting Enzyme 2–Independent Action of Presumed Angiotensin-Converting Enzyme 2 Activators: Studies In Vivo, Ex Vivo, and In Vitro

D. Batlle, J. Wysocki, Minghao Ye, 2014, Hypertension.

Angiotensin II Increases H+-ATPase B1 Subunit Expression in Medullary Collecting Ducts

D. Batlle, Ivan Cokic, P. Vallés, 2005, Hypertension.

Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection

G. Randall, J. Henkin, D. Missiakas, 2022, bioRxiv.

Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection

G. Randall, J. Henkin, D. Missiakas, 2023, Life Science Alliance.

Angiotensin II and angiotensin-(1-7) effects on free cytosolic sodium, intracellular pH, and the Na(+)-H+ antiporter in vascular smooth muscle.

D. Batlle, M. Ye, G. Flores, 1996, Hypertension.

ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.

D. Batlle, M. Soler, Y. Kanwar, 2007, Kidney international.